BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32790863)

  • 1. DPP-4 Inhibition with Anagliptin Reduces Lipotoxicity-Induced Insulin Resistance and Steatohepatitis in Male Mice.
    Sakai Y; Chen G; Ni Y; Zhuge F; Xu L; Nagata N; Kaneko S; Ota T; Nagashimada M
    Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32790863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization.
    Zhuge F; Ni Y; Nagashimada M; Nagata N; Xu L; Mukaida N; Kaneko S; Ota T
    Diabetes; 2016 Oct; 65(10):2966-79. PubMed ID: 27445264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects.
    Kawakubo M; Tanaka M; Ochi K; Watanabe A; Saka-Tanaka M; Kanamori Y; Yoshioka N; Yamashita S; Goto M; Itoh M; Shirakawa I; Kanai S; Suzuki H; Sawada M; Ito A; Ishigami M; Fujishiro M; Arima H; Ogawa Y; Suganami T
    Sci Rep; 2020 Jan; 10(1):983. PubMed ID: 31969650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and reversal of lipotoxicity-induced hepatic insulin resistance and steatohepatitis in mice by an antioxidant carotenoid, β-cryptoxanthin.
    Ni Y; Nagashimada M; Zhan L; Nagata N; Kobori M; Sugiura M; Ogawa K; Kaneko S; Ota T
    Endocrinology; 2015 Mar; 156(3):987-99. PubMed ID: 25562616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high-fat diet-fed mice.
    Iwamoto Y; Kimura T; Dan K; Iwamoto H; Sanada J; Fushimi Y; Katakura Y; Shimoda M; Nogami Y; Shirakiya Y; Nakanishi S; Mune T; Kaku K; Kaneto H
    Diabetes Obes Metab; 2024 Jun; 26(6):2339-2348. PubMed ID: 38504118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Honokiol attenuates diet-induced non-alcoholic steatohepatitis by regulating macrophage polarization through activating peroxisome proliferator-activated receptor γ.
    Zhong X; Liu H
    J Gastroenterol Hepatol; 2018 Feb; 33(2):524-532. PubMed ID: 28670854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
    Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
    Elife; 2023 Jan; 12():. PubMed ID: 36648330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression.
    Lee M; Shin E; Bae J; Cho Y; Lee JY; Lee YH; Lee BW; Kang ES; Cha BS
    Sci Rep; 2020 Nov; 10(1):19429. PubMed ID: 33173107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-κB activation.
    Shinjo T; Nakatsu Y; Iwashita M; Sano T; Sakoda H; Ishihara H; Kushiyama A; Fujishiro M; Fukushima T; Tsuchiya Y; Kamata H; Nishimura F; Asano T
    Am J Physiol Endocrinol Metab; 2015 Aug; 309(3):E214-23. PubMed ID: 26015438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl Peptidase-4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation.
    Ikedo T; Minami M; Kataoka H; Hayashi K; Nagata M; Fujikawa R; Higuchi S; Yasui M; Aoki T; Fukuda M; Yokode M; Miyamoto S
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28630262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage p38α promotes nutritional steatohepatitis through M1 polarization.
    Zhang X; Fan L; Wu J; Xu H; Leung WY; Fu K; Wu J; Liu K; Man K; Yang X; Han J; Ren J; Yu J
    J Hepatol; 2019 Jul; 71(1):163-174. PubMed ID: 30914267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits.
    Hirano T; Yamashita S; Takahashi M; Hashimoto H; Mori Y; Goto M
    Metabolism; 2016 Jun; 65(6):893-903. PubMed ID: 27173468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pirfenidone prevents and reverses hepatic insulin resistance and steatohepatitis by polarizing M2 macrophages.
    Chen G; Ni Y; Nagata N; Xu L; Zhuge F; Nagashimada M; Kaneko S; Ota T
    Lab Invest; 2019 Sep; 99(9):1335-1348. PubMed ID: 31019294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis.
    Wang X; Hausding M; Weng SY; Kim YO; Steven S; Klein T; Daiber A; Schuppan D
    Antioxid Redox Signal; 2018 Jan; 28(2):87-109. PubMed ID: 28635324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CX3CL1/CX3CR1 interaction protects against lipotoxicity-induced nonalcoholic steatohepatitis by regulating macrophage migration and M1/M2 status.
    Ni Y; Zhuge F; Ni L; Nagata N; Yamashita T; Mukaida N; Kaneko S; Ota T; Nagashimada M
    Metabolism; 2022 Nov; 136():155272. PubMed ID: 35914622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined treatment of dipeptidyl peptidase-4 inhibitor and exercise training improves lipid profile in KK/Ta mice.
    Tanimura Y; Aoi W; Mizushima K; Higashimura Y; Naito Y
    Exp Physiol; 2019 Jul; 104(7):1051-1060. PubMed ID: 31020720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice.
    Shirakawa J; Fujii H; Ohnuma K; Sato K; Ito Y; Kaji M; Sakamoto E; Koganei M; Sasaki H; Nagashima Y; Amo K; Aoki K; Morimoto C; Takeda E; Terauchi Y
    Diabetes; 2011 Apr; 60(4):1246-57. PubMed ID: 21330637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-type natriuretic peptide (CNP) in endothelial cells attenuates hepatic fibrosis and inflammation in non-alcoholic steatohepatitis.
    Bae CR; Hino J; Hosoda H; Miyazato M; Kangawa K
    Life Sci; 2018 Sep; 209():349-356. PubMed ID: 30114411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of lipid-induced macrophage polarization through modulating peroxisome proliferator-activated receptor-gamma activity affects hepatic lipid metabolism via a Toll-like receptor 4/NF-κB signaling pathway.
    Wu HM; Ni XX; Xu QY; Wang Q; Li XY; Hua J
    J Gastroenterol Hepatol; 2020 Nov; 35(11):1998-2008. PubMed ID: 32128893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Astaxanthin prevents and reverses diet-induced insulin resistance and steatohepatitis in mice: A comparison with vitamin E.
    Ni Y; Nagashimada M; Zhuge F; Zhan L; Nagata N; Tsutsui A; Nakanuma Y; Kaneko S; Ota T
    Sci Rep; 2015 Nov; 5():17192. PubMed ID: 26603489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.